


Supplemental Figure 1. Synthesis of VU6036720.



Supplemental Figure 2. *In vivo* renal clearance studies. Mice were gavaged with either vehicle (n=10), 30 mg/kg VU6036720 (n=10), 100 mg/kg VU6036720 (n=7), or HCTZ (n=3) and placed in metabolic cages for a 4h urine-collection period. Values are individual and means \pm SD urine volumes. There were no significant ($P < 0.05$) differences between vehicle and VU6036720 treatments, whereas HCTZ induced a significant ($P < 0.02$) increase in urine volume compared to vehicle treatment.